Efficacy and Safety of the Recombinant Zoster Vaccine in Adults 50 Years of Age or Older
Cited in blog · The New England Journal of Medicine, 385, 220-232. · 2021
Canac-Marquis M et al. (2021). Efficacy and Safety of the Recombinant Zoster Vaccine in Adults 50 Years of Age or Older. *The New England Journal of Medicine*, 385, 220-232.
Authors
Canac-Marquis M et al.
Research lens
Canac-Marquis M et al. (2021). Efficacy and Safety of the Recombinant Zoster Vaccine in Adults 50 Years of Age or Older. *The New England Journal of Medicine*, 385, 220-232.
- blog
- shingles-vaccine-dementia-risk-2026-08-13